Residential College | false |
Status | 已發表Published |
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations | |
Lin G.-W.; Xu C.; Chen K.; Huang H.-Q.; Chen J.; Song B.; Chan J.K.C.; Li W.; Liu W.; Shih L.-Y.; Chuang W.-Y.; Kim W.S.; Tan W.; Peng R.-J.; Laurensia Y.; Cheah D.M.Z.; Huang D.; Cheng C.L.; Su Y.-J.; Tan S.-Y.; Ng S.-B.; Tang T.P.L.; Han K.; Wang V.Y.-F.; Jia W.-H.; Pei Z.; Li Y.-J.; Gao S.; Shi Y.; Hu Z.; Zhang F.; Zhang B.; Zeng Y.-X.; Shen H.; He L.; Ong C.K.; Lim S.T.; Chanock S.; Kwong Y.-L.; Lin D.; Rothman N.; Khor C.C.; Lan Q.; Bei J.-X.; Au W.-Y.; Chiu B.; Fan L.; Li Z.; LAM T.H.; Liang R.; Yeh S.-P.; Xu J.; Ip D.K.M.; Li G.; Xu G.; Wang X.; Bai O.; Cai Q.-Q.; Xia Y.; Chen J.-R.; Luo C.-L.; Xiong X.-Y.; Zeng Y.; Wei P.-P.; Liu C.-J.; Liu Y.-X.; Cao Y.-L.; He S.; Liu Y.; Ha J.C.H.; Khoo L.P.; Kee R.X.; Tan J.; Liu Y.; Zhang F.; Feng Y.; Rao H.; Chng W.J.; Chan J.Y.S.; Somasundaram N.D.; Tao M.; Ras M.F.B.H.; Yeoh K.-W.; Goh Y.T.; Ong S.Y.; Grigoropoulos N.F.; Wong E.K.Y.; Pang J.W.L.; Lim J.Q.; Chia B.K.H.; Kim S.J.; Yoon S.E.; Choi S.; Kuo C.-Y.; Chen T.-Y.; Su Y.-C.; Huang W.-T.; Lee M.-Y.; Yao W.; Ngan K.-C.; Liu H.; Lee H.; Yip S.-F.; Liu J.; Li J.; Rabkin C.S.; Berndt S.; Bassig B.; Hu W.; Zhao M.; Li Y.; Zhai Q.; Shao Z.; Qiu L.; Wang J.; Xu F.-P.; Chen L.; Hou Y.; Xu S.; Huang Z.; Xie M.; Li M.; Zhong S.; Zhang Y.; Gu D.; Wang X.; Foo J.N.; Li Z.; Dai J.; Sun L.; Wang Z.; Liu H.; Zhou H.; Sun Y.; Koh W.-P.; Heng C.-K.; Hong C.S.; Ahn J.; Park K.H.; Tin A.; Gu J.; Xia X.; Li B.; Yu X.; International NKTCL Working Group | |
2020 | |
Source Publication | The Lancet Oncology |
ISSN | 1470-2045 |
Volume | 21Issue:2Pages:306-316 |
Abstract | Background: Extranodal natural killer T-cell lymphoma (NKTCL; nasal type) is an aggressive malignancy with a particularly high prevalence in Asian and Latin American populations. Epstein-Barr virus infection has a role in the pathogenesis of NKTCL, and HLA-DPB1 variants are risk factors for the disease. We aimed to identify additional novel genetic variants affecting risk of NKTCL. Methods: We did a genome-wide association study of NKTCL in multiple populations from east Asia. We recruited a discovery cohort of 700 cases with NKTCL and 7752 controls without NKTCL of Han Chinese ancestry from 19 centres in southern, central, and northern regions of China, and four independent replication samples including 717 cases and 12 650 controls. Three of these independent samples (451 cases and 5301 controls) were from eight centres in the same regions of southern, central, and northern China, and the fourth (266 cases and 7349 controls) was from 11 centres in Hong Kong, Taiwan, Singapore, and South Korea. All cases had primary NKTCL that was confirmed histopathologically, and matching with controls was based on geographical region and self-reported ancestry. Logistic regression analysis was done independently by geographical regions, followed by fixed-effect meta-analyses, to identify susceptibility loci. Bioinformatic approaches, including expression quantitative trait loci, binding motif and transcriptome analyses, and biological experiments were done to fine-map and explore the functional relevance of genome-wide association loci to the development of NKTCL. Findings: Genetic data were gathered between Jan 1, 2008, and Jan 23, 2019. Meta-analysis of all samples (a total of 1417 cases and 20 402 controls) identified two novel loci significantly associated with NKTCL: IL18RAP on 2q12.1 (rs13015714; p=2·83 × 10−16; odds ratio 1·39 [95% CI 1·28–1·50]) and HLA-DRB1 on 6p21.3 (rs9271588; 9·35 × 10−26 1·53 [1·41–1·65]). Fine-mapping and experimental analyses showed that rs1420106 at the promoter of IL18RAP was highly correlated with rs13015714, and the rs1420106-A risk variant had an upregulatory effect on IL18RAP expression. Cell growth assays in two NKTCL cell lines (YT and SNK-6 cells) showed that knockdown of IL18RAP inhibited cell proliferation by cell cycle arrest in NKTCL cells. Haplotype association analysis showed that haplotype 47F-67I was associated with reduced risk of NKTCL, whereas 47Y-67L was associated with increased risk of NKTCL. These two positions are component parts of the peptide-binding pocket 7 (P7) of the HLA-DR heterodimer, suggesting that these alterations might account for the association at HLA-DRB1, independent of the previously reported HLA-DPB1 variants. Interpretation: Our findings provide new insights into the development of NKTCL by showing the importance of inflammation and immune regulation through the IL18–IL18RAP axis and antigen presentation involving HLA-DRB1, which might help to identify potential therapeutic targets. Taken in combination with additional genetic and other risk factors, our results could potentially be used to stratify people at high risk of NKTCL for targeted prevention. Funding: Guangdong Innovative and Entrepreneurial Research Team Program, National Natural Science Foundation of China, National Program for Support of Top-Notch Young Professionals, Chang Jiang Scholars Program, Singapore Ministry of Health's National Medical Research Council, Tanoto Foundation, National Research Foundation Singapore, Chang Gung Memorial Hospital, Recruitment Program for Young Professionals of China, First Affiliated Hospital and Army Medical University, US National Institutes of Health, and US National Cancer Institute. © 2020 Elsevier Ltd |
DOI | 10.1016/S1470-2045(19)30799-5 |
URL | View the original |
WOS ID | WOS:000510481800039 |
Publisher | Lancet Publishing Group |
Scopus ID | 2-s2.0-85078420623 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences |
Affiliation | 1.Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 2.Department of Lymphoma, Guangdong Academy of Medical Sciences, Guangzhou, China 3.Department of Pathology, Guangdong Academy of Medical Sciences, Guangzhou, China 4.Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 5.Hematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, Chengdu, China 6.Department of Pathology, West China Hospital, Sichuan University, Chengdu, China 7.Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 8.Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China 9.Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China 10.Department of Pathology, Queen Elizabeth HospitalHong Kong Special Administrative Region, Hong Kong 11.Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan 12.Chang Gung University, Taoyuan, Taiwan 13.Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan 14.Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 15.Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 16.Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 17.Department of Pathology, Singapore General Hospital, Singapore 18.Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 19.Cancer Science Institute of Singapore, National University of Singapore, Singapore 20.Department of Pathology, National University Hospital, National University Health System, Singapore 21.Institute of Molecular and Cell Biology, A*STAR, Singapore 22.Department of Pathology, University of Malaya, Kuala Lumpur, Malaysia 23.Division of Medical Oncology, National Cancer Centre Singapore, Singapore 24.Department of Nanobiomedical Science, BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, South Korea 25.Faculty of Health Sciences, University of Macau, Macau Special Administrative Region, China 26.Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China 27.Center for Precision Medicine, Sun Yat-sen University, Guangzhou, China 28.Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China 29.The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China 30.The Affiliated Hospital of Qingdao University & the Biomedical Sciences Institute of Qingdao University, Qingdao Branch of SJTU Bio-X Institutes, Qingdao University, Qingdao, China 31.Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), the Collaborative Innovation Center for Brain Science, Shanghai Jiao Tong University, Shanghai, China 32.Shanghai Key Laboratory of Sleep Disordered Breathing, Shanghai, China 33.Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China 34.Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China 35.Department of Epidemiology and Biostatistics, First Affiliated Hospital, Army Medical University, Chongqing, China 36.Genome Institute of Singapore, Singapore 37.Duke-NUS Medical School, Singapore 38.SingHealth Duke-NUS Blood Cancer Centre, Singapore 39.Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States 40.Department of Medicine, Queen Mary HospitalHong Kong Special Administrative Region, Hong Kong 41.Singapore Eye Research Institute, Singapore |
Recommended Citation GB/T 7714 | Lin G.-W.,Xu C.,Chen K.,et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations[J]. The Lancet Oncology, 2020, 21(2), 306-316. |
APA | Lin G.-W.., Xu C.., Chen K.., Huang H.-Q.., Chen J.., Song B.., Chan J.K.C.., Li W.., Liu W.., Shih L.-Y.., Chuang W.-Y.., Kim W.S.., Tan W.., Peng R.-J.., Laurensia Y.., Cheah D.M.Z.., Huang D.., Cheng C.L.., Su Y.-J.., ...& International NKTCL Working Group (2020). Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. The Lancet Oncology, 21(2), 306-316. |
MLA | Lin G.-W.,et al."Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations".The Lancet Oncology 21.2(2020):306-316. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment